Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction

The diagnosis of clear cell (CC) carcinoma of the endometrium can be challenging, especially when endometrioid (EC) and serous (SC) endometrial cancers exhibit nonspecific clear cell changes, in carcinomas with mixed histology and in the setting of Arias-Stella reaction (ASR). In this study, classic CC immunohistochemical markers (Napsin A, HNF-1β, and ER) and 2 recent novel markers, cystathionine gamma-lyase (CTH) and arginosuccinate synthase (ASS1), are assessed for their utility in distinguishing CC from its morphologic mimics. Tissue microarrays containing 64 CC, 128 EC, 5 EC with clear cell change, 16 SC, 5 mixed carcinomas, and 11 whole ASR sections were stained, with 12 additional examples of ASR stained subsequently. A cutoff of 70% and moderate intensity were used for HNF-1β, 80% of cells and strong intensity were used for CTH, and any staining was considered positive for the remaining markers. For differentiating CC from pure EC and SC, HNF-1β, Napsin A, and CTH all performed well. HNF-1β had higher specificity (99.3% vs. 95.1%) but lower sensitivity (55.8% vs. 73.1%) compared with Napsin A. CTH did not substantially outperform HNF- 1β or Napsin A (sensitivity 51.9%, specificity 99.3%). ASS1 and ER were not helpful (specificities of 60.1% and 22.6%). For differentiating CC from ASR, HNF-1β, Napsin A, and CTH stained a large proportion of ASR and were not useful. However, ER positivity and ASS1 negativity were helpful for identifying ASR (specificity 88.2% and 95.1%, respectively). EC with clear cell changes exhibited immunohistochemical patterns similar to pure EC (HNF-1β−, ER+, and CTH−). No markers were useful in confirming the CC components in mixed carcinomas.

[1]  P. Ip,et al.  Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1&bgr;), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction , 2019, The American journal of surgical pathology.

[2]  C. Gilks,et al.  Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[3]  O. Fadare,et al.  Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis , 2018, International journal of surgical pathology.

[4]  Nadeem Shafique Butt,et al.  Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  D. Huntsman,et al.  Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? , 2017, The Journal of pathology.

[6]  Juan Ye,et al.  Cystathionine- γ-lyase promotes process of breast cancer in association with STAT3 signaling pathway , 2017, Oncotarget.

[7]  G. Birdsong,et al.  Recent Developments in Surgical Pathology of the Uterine Corpus. , 2017, Archives of pathology & laboratory medicine.

[8]  Gregg B. Morin,et al.  Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research , 2016, Scientific Reports.

[9]  Omar S. Gómez,et al.  Cystathionine: A novel oncometabolite in human breast cancer. , 2016, Archives of Biochemistry and Biophysics.

[10]  O. Fadare Expression of Napsin A is common in Arias-Stella reaction. , 2016, Human pathology.

[11]  J. Prat,et al.  Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features , 2016, The American journal of surgical pathology.

[12]  O. Fadare,et al.  Arias-Stella Reaction in Progestin-Treated Endometrioid Adenocarcinoma , 2016, International journal of surgical pathology.

[13]  M. Köbel,et al.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases , 2015, The American journal of surgical pathology.

[14]  Meenakshi Singh,et al.  Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. , 2016, American journal of clinical pathology.

[15]  P. Dundr,et al.  Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions , 2016, Pathology and Oncology Research.

[16]  E. Oliva,et al.  Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma , 2015, The American journal of surgical pathology.

[17]  M. Köbel,et al.  Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1&bgr; , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[18]  Y. Nakatani,et al.  Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. , 2015, Human pathology.

[19]  Chengquan Zhao,et al.  Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours , 2015, Pathology.

[20]  Insun Kim,et al.  Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma? , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  B. Karlan,et al.  Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas , 2014, The journal of pathology. Clinical research.

[22]  S. Toyokuni,et al.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma , 2015, Modern Pathology.

[23]  Chao Zhao,et al.  Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer. , 2014, Cellular signalling.

[24]  M. Yasuda Immunohistochemical characterization of endometrial carcinomas: Endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis , 2014, The journal of obstetrics and gynaecology research.

[25]  H. Lee,et al.  Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin , 2014, Histopathology.

[26]  C. Shao,et al.  Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells. , 2014, Mutation research.

[27]  D. Huntsman,et al.  Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF‐1β and oestrogen receptor , 2014, Histopathology.

[28]  J. Hecht,et al.  Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility , 2014, The American journal of surgical pathology.

[29]  S. Leung,et al.  HNF-1&bgr; in Ovarian Carcinomas With Serous and Clear Cell Change , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[30]  C Blake Gilks,et al.  Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.

[31]  J. Hecht,et al.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. , 2013, American journal of cancer research.

[32]  O. Fadare,et al.  Diagnostic Utility of Hepatocyte Nuclear Factor 1-Beta Immunoreactivity in Endometrial Carcinomas: Lack of Specificity For Endometrial Clear Cell Carcinoma , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[33]  Y. Jeng,et al.  Utility of hepatocyte nuclear factor‐1β as a diagnostic marker in ovarian carcinomas with clear cells , 2012, Histopathology.

[34]  Dennis C. Sgroi,et al.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes , 2016 .

[35]  Thomas Zeng,et al.  Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.

[36]  E. Pirog,et al.  The Diagnosis of Endometrial Carcinomas With Clear Cells by Gynecologic Pathologists: An Assessment of Interobserver Variability and Associated Morphologic Features , 2012, The American journal of surgical pathology.

[37]  S. Wiseman,et al.  Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas , 2011, The Journal of pathology.

[38]  A. Gadducci,et al.  Clear cell carcinoma of the endometrium: a biological and clinical enigma. , 2010, Anticancer research.

[39]  A. Olawaiye,et al.  Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[40]  H. Tsuda,et al.  Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. , 2007, Human pathology.

[41]  D. Wheatley Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. , 2005, Seminars in cancer biology.

[42]  R. Vang,et al.  Immunohistochemical Staining for Ki-67 and p53 Helps Distinguish Endometrial Arias-Stella Reaction from High-Grade Carcinoma, Including Clear Cell Carcinoma , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[43]  J. Arias-Stella The Arias-Stella Reaction: Facts and Fancies Four Decades After , 2002, Advances in anatomic pathology.

[44]  R. Kurman,et al.  Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. , 1998, Human pathology.

[45]  P. Huettner,et al.  Arias-Stella reaction in nonpregnant women: a clinicopathologic study of nine cases. , 1994, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[46]  V. Gould,et al.  Arias-Stella reaction with prominent nuclear pseudoinclusions simulating herpetic endometritis. , 1982, Diagnostic gynecology and obstetrics.

[47]  W. Welch,et al.  Precancerous lesions of the endometrium. , 1977, Human pathology.

[48]  J. Azzopardi,et al.  Synthetic progestogen-oestrogen therapy and uterine changes , 1967, Journal of clinical pathology.

[49]  R. Fienberg,et al.  THE ARIAS-STELLA REACTION: A NONSPECIFIC INVOLUTIONAL PHENOMENON IN INTRA- AS WELL AS EXTRAUTERINE PREGNANCY. , 1965, American journal of clinical pathology.

[50]  J. Arias-Stella Abnormal endometrial changes induced in the rat; the effects of chorionic hormone and estrogen. , 1955, A.M.A. archives of pathology.

[51]  J. Arias-Stella Atypical endometrial changes associated with the presence of chorionic tissue. , 1954, A.M.A. archives of pathology.